Revisiting the Trips Regime: Rwanda-Canadian ARV Drug Deal Tests the WTO General Council Decision

Simple item page
dc.contributor.authorRebecca, Amollo
dc.date.accessioned2019-10-07T12:42:24Z
dc.date.available2019-10-07T12:42:24Z
dc.date.issued2009
dc.description.abstractOn 17 July 2007, the world was awakened to Rwanda's notification of the World Trade Organisation's (WTO) Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) that it plans to import the HIV-drug TriAvir from Canada's giant pharmaceuticals company, Apotex. Two months later, Canada issued a compulsory licence allowing Apotex to use nine patented inventions for manufacturing and exporting TriAvir to Rwanda. On 4 October 2007, Canada notified the Council for TRIPS of the compulsory licence. In September 2008, Apotex said it will ship seven million antiretroviral pills to Rwanda to treat 21,000 patients. Against this backdrop, this article uses the Rwandan-Canadian drug deal to examine the utility of the WTO General Council Decision in making ARV drugs more accessible to Low and Middle Income Countries so far. In doing so, the article's analyses rely on the regime of the Canadian Access to Medicines Regime which was enacted after the WTO Decision. The author discusses some of the issues arising from the deal in light of the effectiveness of the General Council Decision in solving the problem of access to antiretroviral drugs within the right to health and HIV/AIDS context. The article also raises questions relating to the willingness of developing countries to take benefit of the TRIPS flexibilities and the obligation of developed countries to ensure that the flexibilities become a reality.en_US
dc.identifier.citationAmollo, R. 2009. Revisiting the TRIPS regime: Rwanda-Canadian ARV drug deal tests the WTO General Council decision. African Journal of International and Comparative Law, 17(2), 240-269.en_US
dc.identifier.urihttp://hdl.handle.net/10566/5015
dc.language.isoenen_US
dc.publisherAfrican Journal of International and Comparative Lawen_US
dc.subjectWorld Trade Organisationen_US
dc.subjectTrade-Related Aspects of Intellectual Property Rightsen_US
dc.subjectRwandaen_US
dc.subjectAccess to medicinesen_US
dc.subjectPharmaceutical industryen_US
dc.subjectAntiretroviral drugsen_US
dc.titleRevisiting the Trips Regime: Rwanda-Canadian ARV Drug Deal Tests the WTO General Council Decisionen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Amollo_revisiting the TRIPS regime_2009.pdf
Size:
1.92 MB
Format:
Adobe Portable Document Format
Description:
Amollo_revisiting TRIPS regime_2009
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Socio-Economic Rights Project (SERP)